Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

PepGen Inc

PEPG ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.99

▲ +0.34%

Market Cap $207.09M · Vol 122.55K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$207.09M

Micro Cap

Div Yield

N/A

EPS Growth

+45.75%

YoY

RSI (14)

82.25

Momentum

Beta

2.05

vs Market

52W High

$7.80

61.67% below

52W Low

$1.13

164.60% above

Volume

122.55K

Avg 296.15K

P/B

3.04

Price-to-book

ROE

-67.39%

Return on equity

Free Float

99.77%

Public shares

Shariah Compliance8 STANDARDS

✗ PepGen Inc (PEPG) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PEPG pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.91%

+22.54%

+81.21%

-53.57%

YTD

-54.07%

+131.78%

-49.06%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-89,655,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-67.39%
ROA · ROIC	-55.18% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.04
P/FCF	N/A
EPS Growth	+45.75%
Outstanding Shares	69.26M

Technical Indicators

50-Day SMA	$2.00
200-Day SMA	$3.77
RSI (14)	82.25
Beta	2.05
52-Week High	$7.80
52-Week Low	$1.13

Volume Today	122.55K
Avg Daily Volume (30D)	296.15K
Relative Volume	0.41x
Volatility (10D)	109.93
Volatility (30D)	108.75
Free Float	99.77%

Analyst Consensus

BUY

Current Price $2.99

Mean Target $10.19

52W Low$1.13 52W High$7.80

Current

Target

$1.13 $7.80

Current Analyst target

+240.72% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG012232627

ISINUS7133171055

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.